Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U057 - Hyperhidrosis: Update on Therapeutics

Sunday, February 18; 7:00 AM - 8:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Diagnose primary focal hyperhidrosis.
  • Manage hyperhidrosis in the pediatric patient.
  • Formulate a tailored approach to each individual hyperhidrosis patient based on their particular needs, symptoms, and response to treatment.

Description

This session serves as a basic overview of hyperhidrosis, or sweat in excess of that required for thermoregulation. Diagnosis and treatment modalities will be covered, including topical therapy, medical management, iontophoresis, botulinum toxin injection, and the use of various devices/surgical management. Additionally, the session will cover the unique challenges when approaching the pediatric patient with excess sweating.

Disclosures

  • Council, Martha Laurin, MD: MDoutlook – C(H); Medline Industries, Inc. – C(H);
  • Glaser, Dee Anna, MD: Allergan, Inc. – I(Grants/Research Funding), O(H); Dermira – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H); Galderma Research & Development, LLC – I(Grants/Research Funding); Miramar Labs – C(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Unilever Home & Personal Care USA – A(H);
  • Hebert, Adelaide A., MD: Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding), SP(H); Anacor Pharmaceuticals, Inc. – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Bayer – SP(H); Cassiopia – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chugai Pharma – I(Grants/Research Funding); Cutanea Life Sciences – A(H), I(Grants/Research Funding); Department of DEFENSE – O(Grants/Research Funding); Dermavant Sciences – I(Grants/Research Funding); Dermira – A(H), I(Grants/Research Funding); Encore Dermatology, Inc. – A(H); Galderma Laboratories, L.P. – A(H), SP(H); GlaxoSmithKline – A(H), Data Safety Monitoring Board(H), I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – SP(H); Mayne Pharma Group – I(Grants/Research Funding); Medimetriks Pharmaceuticals, Inc. – I(Grants/Research Funding); Menarini Group – SP(H); Menlo Therapeutics – A(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); NIH – I(Grants/Research Funding); Novan – I(H); Novartis Pharmaceuticals Corp. – O(H); Onset Therapeutics – SP(H); Ortho Dermatologics – A(H); Pfizer Inc. – Speaker/Faculty Education(H); Pharmaderm – A(H); PPD Inc. – I(Grants/Research Funding); Prim-Med – SP(H); Promius Pharma, LLC – A(H); Promius Pharmaceuticals – A(H), I(Grants/Research Funding); Regeneron – Data Safety Monitoring Board(H); Roivant Sciences – A(H); Shionogi USA – A(IP); Sienna Biopharmaceuticals – I(Grants/Research Funding); Sinclair Pharma – SP(H); Stiefel a GSK company – A(H); TopMD – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), SP(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding);
  • Pariser, David Michael, MD: Abbott Laboratories – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Asana Biosciences, LLC – I(Grants/Research Funding); Atacama Therapeutics – C(H); Bickel Biotechnology – C(H), I(Grants/Research Funding); Biofrontera AG – C(H); Celgene Corporation – C(H), I(Grants/Research Funding); Dermavant Sciences – I(Grants/Research Funding); Dermira – C(H); DUSA Pharmaceuticals, Inc. – C(H); Eli Lilly and Company – I(Grants/Research Funding); LEO Pharma, US – C(H), I(Grants/Research Funding), I(H); Merck & Co., Inc – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Novo Nordisk A/S – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Peplin Inc. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(H); Photocure ASA – I(Grants/Research Funding); Promius Pharmaceuticals – C(H), I(Grants/Research Funding); Regeneron – C(H), I(Grants/Research Funding); Sanofi – C(H); Stiefel a GSK company – I(Grants/Research Funding); TDM SurgiTech, Inc. – C(H); TheraVida – C(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding);
  • Peterson, Jennifer D., MD: Allergan, Inc – Speaker/Faculty Education(H); Galderma USA – Speaker/Faculty Education(H); Lumenis – A(NC), I(Grants/Research Funding), Speaker/Faculty Education(H); Merz Aesthetics – A(NC), C(H), I(Grants/Research Funding); Miramar Labs – SP(H); Revance Therapeutics, Inc. – I(Grants/Research Funding);
Schedule
Sunday, February 18
7:00 AM
Dr. Council / Introduction
7:05 AM
Dr. Pariser / Medical Management and Iontophoresis
7:20 AM
Dr. Glaser / Use of Botulinum Toxin
7:35 AM
Dr. Hebert / Approach to the Pediatric Patient
7:50 AM
Dr. Peterson / Surgical Management and Use of Devices
Event Details
  • Date
    Sunday, February 18
  • Time
    7:00 AM - 8:00 AM
  • Location
    Room 28A
  • CME Credits
    1.00
  • Type
Directors/Co-Directors
  • Martha Laurin Council, MD, FAAD
Speakers
  • Adelaide A. Hebert, MD, FAAD - Handout
  • David Michael Pariser, MD, FAAD
  • Dee Anna Glaser, MD, FAAD - Handout
  • Jennifer D. Peterson, MD, FAAD